Pfizer Inc. (PFE): Trouble Ahead For The Stock
Tara Clarke: Pfizer Inc. (NYSE:PFE) will soon feel the pressure from the wave of lawsuits being filed claiming that Pfizer’s blockbuster drug Lipitor – the world’s best-selling drug of all time – causes type-2 diabetes in women.
With a market cap of more than $180 billion, the world’s largest pharmaceutical firm’s pockets run deep. Lipitor alone brought in global sales of more than $125 billion for Pfizer over the 14-and-a-half years since its 1996 market debut (Pfizer’s patent on Lipitor expired on November 30, 2011). More than 29 million patients took the drug just in the United States.
A recent Reuters review of federal court filings discovered that Lipitor claims have shot up from 56 to nearly 1,000 in the past five months.
That’s because of a Feb. 18 decision by the U.S. Judicial Panel on Multidistrict Litigation.
The Panel determined that the number of Lipitor diabetes lawsuit filings had gotten large enough to warrant their consolidation in a single, federal court proceeding. While Pfizer argued against a consolidation, stating that doing so would prompt copycat filings, the Panel ruled that merging the cases would prove beneficial for both plaintiffs and Pfizer.
A U.S. District Court located in Charleston, South Carolina, will handle the consolidated proceedings and U.S. District Judge Richard M. Gergel will preside. The first case is scheduled to be tried in July 2015.
It will serve as one of several “bellwether” cases to gauge the strength of other cases in the pool of claims.
Pfizer issued a statement denying any liability and stated its intention to fight the lawsuits. The company has argued that women taking Lipitor to control cholesterol may share other risk factors that make them vulnerable to diabetes, such as high blood pressure or obesity. It also stated that there is an “overwhelming consensus” in the medical community about the benefits of statins, including Lipitor.
A twist to this story is that the U.S. Food and Drug Administration warned Pfizer in 2012 that Lipitor and other statin-type cholesterol-reducing drugs were linked to incidents of memory loss and a “small increased risk” of diabetes. Plaintiffs’ lawyers have argued that Pfizer failed to properly warn the public of these risks. They’ve also said that women face a higher risk than men of developing diabetes from using Lipitor, while also gaining fewer benefits.